Item 2. Unregistered Sales of Equity Securities
Item
2. Unregistered Sales of Equity Securities and Use of Proceeds.
On March 19, 2024, we entered into an At-The-Market Issuance Sales
Agreement, as may be amended from time to time (the “Sales Agreement”) with Ascendiant Capital Markets, LLC (“Ascendiant”)
under which we may, from time to time, issue and sell shares of our Common Stock having aggregate sales proceeds of up to $30 million,
in a series of one or more “at-the-market” equity offerings (the “ATM Program”). Ascendiant is not required to
sell any specific share amounts but acts as our sales agent, using commercially reasonable efforts consistent with its normal trading
and sales practices. We agreed to pay Ascendiant a commission equal to 3.0% of the aggregate gross proceeds we receive from each sale
of shares of our Common Stock. Pursuant to the Sales Agreement, any shares will be sold pursuant to our shelf registration statement on
Form S-3 (File No. 333-275282) filed with the SEC on November 2, 2023, including the base prospectus contained therein, as declared effective
by the SEC on November 29, 2023. Shares of our Common Stock will be sold at prevailing market prices at the time of the sale, and as a
result, prices may vary.
During
the period April 1, 2024, through August 5, 2024, the Company has sold 7,340,312 shares of its Common Stock for net proceeds of $1,404.
Item
3. Defaults Upon Senior Securities.
For
a discussion of the “ Convertible Promissory Note Due to Novartis ” refer to Note 5 to the Condensed Consolidated Financial
Statements (Unaudited) in Part I, Item 1 of this Quarterly Report.
Item
4. Mine Safety Disclosures.
Not
applicable.
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.